Clinical Trial Update: Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating Fluzopari in combination with Apatinib for neoadjuvant treatment of unresectable ovarian cancer. Current status is un…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Apatinib (apatinib)
• Fluzopari

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Ovarian Cancer | Phase 2 | Status: UNKNOWN